Evidence map›Paper›PMID 29422059›Full record

ArticleJournal of neuroinflammation2018

Hyperammonemia alters membrane expression of GluA1 and GluA2 subunits of AMPA receptors in hippocampus by enhancing activation of the IL-1 receptor: underlying mechanisms.

Lucas Taoro-Gonzalez, Yaiza M Arenas, Andrea Cabrera-Pastor, Vicente Felipo

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Enhancement of Memory and Synaptic Plasticity byTheScientificWorldJournal · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments.Journal of the Chinese Medical Association : JCMA · 2024
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lucas Taoro-GonzalezLaboratory of Neurobiology, Centro de Investigacion Príncipe Felipe, Eduardo Primo Yufera 3, 46012, Valencia, Spain. ltaoro@cipf.es.
Yaiza M ArenasLaboratory of Neurobiology, Centro de Investigacion Príncipe Felipe, Eduardo Primo Yufera 3, 46012, Valencia, Spain.
Andrea Cabrera-PastorLaboratory of Neurobiology, Centro de Investigacion Príncipe Felipe, Eduardo Primo Yufera 3, 46012, Valencia, Spain.
Vicente FelipoLaboratory of Neurobiology, Centro de Investigacion Príncipe Felipe, Eduardo Primo Yufera 3, 46012, Valencia, Spain.ORCID http://orcid.org/0000-0003-3145-9538
Centro de Investigacion Principe Felipe · ES

Funding

Consellería Educación Generalitat Valenciana PROMETEOII/2014/033European Regional Development Funds PROMETEOII/2014/033European Regional Development Funds SAF2014-51851-RMinisterio de Ciencia e Innovación SAF2014-51851-RMinisterio de Educación, Cultura y Deporte FPU13/02492
6 · The paper itself

Abstract

backgroundHyperammonemic rats reproduce the cognitive alterations of patients with hepatic encephalopathy, including altered spatial memory, attributed to altered membrane expression of AMPA receptor subunits in hippocampus. Neuroinflammation mediates these cognitive alterations. We hypothesized that hyperammonemia-induced increase in IL-1β in hippocampus would be responsible for the altered GluA1 and GluA2 membrane expression. The aims of this work were to (1) assess if increased IL-1β levels and activation of its receptor are responsible for the changes in GluA1 and/or GluA2 membrane expression in hyperammonemia and (2) identify the mechanisms by which activation of IL-1 receptor leads to altered membrane expression of GluA1 and GluA2.

methodsWe analyzed in hippocampal slices from control and hyperammonemic rat membrane expression of AMPA receptors using the BS3 cross-linker and phosphorylation of the GluA1 and GluA2 subunits using phosphor-specific antibodies. The IL-1 receptor was blocked with IL-Ra, and the signal transduction pathways involved in modulation of membrane expression of GluA1 and GluA2 were analyzed using inhibitors of key steps.

resultsHyperammonemia reduces GluA1 and increases GluA2 membrane expression and reduces phosphorylation of GluA1 at Ser831 and of GluA2 at Ser880. Hyperammonemia increases IL-1β, enhancing activation of IL-1 receptor. This leads to activation of Src. The changes in membrane expression of GluA1 and GluA2 are reversed by blocking the IL-1 receptor with IL-1Ra or by inhibiting Src with PP2. After Src activation, the pathways for GluA2 and GluA1 diverge. Src increases phosphorylation of GluN2B at Tyr14721 and membrane expression of GluN2B in hyperammonemic rats, leading to activation of MAP kinase p38, which binds to and reduces phosphorylation at Thr560 and activity of PKCζ, resulting in reduced phosphorylation at Ser880 and enhanced membrane expression of GluA2. Increased Src activity in hyperammonemic rats also activates PKCδ which enhances phosphorylation of GluN2B at Ser1303, reducing membrane expression of CaMKII and phosphorylation at Ser831 and membrane expression of GluA1.

conclusionsThis work identifies two pathways by which neuroinflammation alters glutamatergic neurotransmission in hippocampus. The steps of the pathways identified could be targets to normalize neurotransmission in hyperammonemia and other pathologies associated with increased IL-1β by acting, for example, on p38 or PKCδ. IL-1β alters membrane expression of GluA1 and GluA2 AMPA receptor subunits by two difrerent mechanisms in the hippocampus of hyperammonemic rats.

Indexed as

AcetatesAnimalsCell MembraneGene ExpressionHippocampusHyperammonemiaInterleukin 1 Receptor Antagonist ProteinMaleProtein SubunitsRatsRats, WistarReceptors, AMPAReceptors, Interleukin-1 Type IAcetatesammonium acetateglutamate receptor ionotropic, AMPA 2Interleukin 1 Receptor Antagonist ProteinProtein SubunitsReceptors, AMPAReceptors, Interleukin-1 Type IAMPA receptorsGluA1GluA2Hepatic encephalopathyHyperammonemiaIL-1 receptorIL-1βMembrane expressionNeuroinflammationNeurotransmission

Identifiers

PMID29422059
PMCPMC5806265
OpenAlexW2796509698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.